Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $599.00.

TMO has been the subject of a number of research analyst reports. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. HSBC started coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They issued a "buy" rating and a $610.00 price objective for the company. Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a "neutral" rating and a $620.00 target price for the company. Barclays lowered Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company's stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company's stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently made changes to their positions in the company. Halpern Financial Inc. lifted its position in shares of Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company's stock valued at $27,000 after buying an additional 40 shares in the last quarter. Northwest Financial Advisors purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. True Wealth Design LLC increased its stake in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company's stock worth $29,000 after purchasing an additional 51 shares in the last quarter. Coppell Advisory Solutions LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $33,000. Finally, Live Oak Investment Partners acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $36,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.9 %

Thermo Fisher Scientific stock traded down $5.42 during trading hours on Tuesday, reaching $572.03. The company had a trading volume of 1,381,269 shares, compared to its average volume of 1,601,800. The firm has a market cap of $218.12 billion, a price-to-earnings ratio of 36.92, a P/E/G ratio of 2.44 and a beta of 0.80. Thermo Fisher Scientific has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company has a 50-day moving average price of $566.95 and a 200 day moving average price of $521.68.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analysts' expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.40 EPS. Equities analysts forecast that Thermo Fisher Scientific will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.